In vitro models pertain to biological systems grown and maintained away from a living organism, in petri dishes, flasks, or even microfluidic devices. From 2D screenings to organ-on-a-chip systems, Protheragen provides scalable and cost-effective advanced biological tools to aid researchers. We are integrating scientific rigor with cutting-edge technology as Protheragen, and this is how we are revolutionizing oncology—one model at a time.
Overview of In Vitro Models
In vitro cancer models are separate systems and laboratories that attempt to imitate different facets of human tumor biology. These models greatly contribute to understanding the mechanisms of tumor evolution, drug resistance, and the effectiveness of treatment. In vitro systems are more ethical and economical as compared to in vivo systems. In vitro models provide an easy way to control numerous physical and biochemical factors. Although traditional 2D monolayer cultures are still common, they do not capture the complex tumor microenvironment (TME) and 3D spatial multicellular architecture of real tumors.
The latest development in preclinical cancer research is the use of three-dimensional (3D) models and microengineered systems. These models simulate in vivo environments for more advanced examination of tumor-stroma interactions, immune evasion, and human-relevant therapeutic responses on a gentler level.
Fig. 1 Use of 3D
in vitro models in pre-clinical cancer research. (Martinez-Pacheco S.,
et al., 2021)
Emergence and Architecture of 3D In Vitro Cancer Models
Three-dimensional in vitro (3D) cell culture systems enhance monolayer cultures by reproducing several important aspects of tumor biology, including cell communication (intercellular interaction), organization of multicellular structures (spatial architecture), and the extracellular matrix (ECM) scaffold. These models differ greatly in their design and level of sophistication.
In scaffold-based 3D cultures, the ECM is simulated with a natural or synthetic matrix. As hydrogels, MatrigelTM, alginate, and collagen are favored because of their biocompatibility as well as their ability to promote cell adhesion, migration, and differentiation. Synthetic alternatives such as PEG have more control over stiffness and degradation kinetics, though they lack biological signaling cues.
Multicellular tumor spheroids can be created using forced aggregation or hanging drop methods. Such spheroids enable the study of avascular tumor development, drug diffusion, and hypoxia-driven resistance without needing scaffolds. Like solid tumors in vivo, spheroids consist of an outer ring of proliferating cells, a middle quiescent zone, and a necrotic core, showcasing a proliferative gradient.
Organ-on-a-Chip and Microfluidic Platforms
Bioengineered microscale organotypic models (BMOMs) embed living cells in microfluidic chips that simulate the flow, mechanical stress, and spatial organization of physiological compartments of organs. Such devices have allowed the recapitulation of the dynamics of tumor vasculature, epithelial-mesenchymal transitions, and immune-tumor interactions.
BMOMs utilize microscale laws of physics to control fluid movements in a predictable way. Their small volume requirements make them well-suited for patient-driven cells, circulating tumor cells, and rare biopsy specimens. Importantly, BMOMs enable studies of paracrine signaling because of the higher concentration of soluble factors in small volumes.
3D Bioprinted Tumor Models
3D bioprinting is an emerging technology that allows the precise deposition of cells and biomaterials to create complex, patient-specific tumor models. Using bioinks made from natural or synthetic materials (e.g., collagen, alginate, gelatin), tumor cells, stromal cells, and endothelial cells are layered to form a three-dimensional structure. This model can replicate the heterogeneity and vascularization of human tumors, offering an advanced platform for drug testing, cancer progression, and metastasis studies.
3D bioprinted tumor models offer high spatial resolution, enabling researchers to recreate the tumor's microenvironment with a level of detail that traditional methods cannot achieve.
Our Services
Protheragen aims to help clients accelerate cancer research and drug discovery using their in vitro model development services. Experienced scientists within Protheragen work closely with clients to fully grasp requirements and adapt their services to cultivate the best relationship. From initial consultation to final model validation, comprehensive support is offered.
2D Cell Line-Based Assays
- High-throughput compatible
- Suitable for initial screening of compound libraries
- Assay types include viability, apoptosis, proliferation, and cytotoxicity assays
3D Tumor Spheroid Models
- Generated from immortalized lines or primary cancer cells
- Generated from immortalized lines or primary cancer cells
- Compatible with high-content imaging and automated workflows
Scaffold-Based 3D Models
- Natural matrices (e.g., collagen) or synthetic hydrogels
- Support organoid growth and tissue polarity
- Customizable stiffness and composition for specific tumor types
Co-Culture Systems
- Incorporate stromal cells, fibroblasts, endothelial, and immune cells
- Ideal for studying TME and immune checkpoint responses
- Offered in both 2D and 3D formats
Microfluidic Tumor-on-a-Chip Models
- Simulate vasculature, flow dynamics, and compartmentalization
- Suitable for mechanistic studies of metastasis, extravasation, and angiogenesis
- Custom-designed for specific cancer indications
Patient-Derived Xenograft (PDX) Organoids
- Derived from biopsy or surgical specimens
- Retain genetic and phenotypic fidelity of primary tumors
- Used in personalized drug response prediction
Service Features
- Customizable Model Design: Fully tailored to specific cancer types (e.g., lung, breast, colorectal, glioblastoma) and research goals.
- Multi-Cellular Complexity: Integration of cancer, stromal, endothelial, and immune cells to mimic TME interactions.
- High-Content Imaging: Supports confocal microscopy, live-cell imaging, and multiplexed fluorescence.
- Assay Compatibility: Compatible with ELISA, flow cytometry, RNA-seq, proteomics, and metabolomics platforms.
- Scalable Platforms: Models suited for both exploratory research and high-throughput drug screening.
- Data Integration Services: Omics data mapping, machine learning-based predictive modeling, and pathway analysis.
Whether the goal is to validate a novel compound, understand resistance pathways, or develop a new therapeutic strategy, Protheragen provides the expertise, infrastructure, and innovation necessary to drive success in cancer research. If you are interested in our services, please feel free to contact us.
References
- Martinez-Pacheco, Sarai, and Lorraine O'Driscoll. "Pre-clinical in vitro models used in cancer research: results of a worldwide survey." Cancers 13.23 (2021): 6033.
- Ayuso, Jose M., et al. "Toward improved in vitro models of human cancer." APL bioengineering 5.1 (2021).
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
